TriangleCAR-T cell (NCT05003895)
CAR-T cell trial for Hepatocellular Carcinoma (NCT05003895). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
Lo que dice el vídeo
Lee la transcripción
Hepatocellular carcinoma is among the deadliest cancers worldwide; once it spreads, treatments add months, not years.
The idea: a marker found on nearly every liver cancer cell but not on healthy adult liver, as a target for engineered T cells.
That marker is glypican-3. At the NIH Clinical Center, a patient's T cells are collected, given a humanized receptor for glypican-3, and returned in a single infusion after three days of chemotherapy clears space. Because the protein is absent from normal liver, the hope is that the cells attack tumor and spare the organ around it.
An early safety study for adults whose tumor tests positive, including other cancers carrying the marker. Tim Greten leads it in Bethesda. Public record; not medical advice.
¿Ya estás en un ensayo?
Se convierte en un proyecto que hay que manejar: citas, estudios de imagen, análisis, efectos secundarios y papeleo. Triangle lo mantiene organizado en un solo lugar, para ti o para quien te ayuda.
Organizar mi ensayoPrueba gratuita de 7 días, después $9 al mes. Cancela cuando quieras.
Cómo funcionan estos ensayos: qué es de verdad la fase 1 · preguntas frecuentes No es evidencia clínica.